Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation and immunology (I&I), today announced multiple presentations that ...
Initial clinical data highlight a differentiated safety and pharmacologic profile for PHST001, including target engagement, innate immune activation, and early signals of clinical activity Preclinical ...
Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode ...
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment ...
BEIJING, Apr. 18 (China Economic Net) - China’s brain-computer interface (BCI) industry is moving into a new stage of development, as policymakers, hospitals, and companies seek to translate years of ...
Explore how evolving obesity research is shaping trial design, with a focus on precision, reproducibility, and clinical ...
Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies, today acknowledged ...
Company to participate in Live Virtual Investor Closing Bell segment today, April 16th?at?4:00 PM ET- Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (N ...
Two classic translational blocks are compounded by an execution gap characterized by weak cross-functional mobilization, slow ...
“Clinical trials give patients access to promising new therapies that are not yet widely available — sometimes offering ...
The University of Iowa’s Office of the Vice President for Research awarded funding to 12 research teams from a variety of ...
Rare neurological disease has undergone a meaningful shift over the past decade. Advances in human genetics, expanded access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results